DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Suramin is an investigational drug.
There have been 20 clinical trials for Suramin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 1996.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Prostatic Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Southwest Oncology Group, and Eastern Cooperative Oncology Group.
Recent Clinical Trials for Suramin
|Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant AKI||Rediscovery Life Sciences||Phase 2|
|Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense||European and Developing Countries Clinical Trials Partnership (EDCTP)||Phase 2/Phase 3|
|Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense||Drugs for Neglected Diseases||Phase 2/Phase 3|